
Pharmacally
ESLD
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in ESLD
Health TidingsResolution Reports 42% Lower Clinical Event Risk in ESLD, Advances RTX001 Towards US Pivotal TrialResolution Therapeutics reported a 42% relative reduction in composite clinical events with RTX001 in the six-month interim analysis of its Phase I/II EMERALD trial.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.